HBVtech presentation at the Hep-DART 2025 conference

The HEP-DART 2025 conference assembles clinicians, researchers, basic scientists, nurses, and physician assistants to advance knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and hepatocellular carcinoma (HCC). This workshop blends the areas of biology, chemistry, pharmacology, and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease, and cancer.

Dr. Yong-Yuan Zhang, MD, PhD, Founder and CSO of HBVtech, will be presenting a poster entitled: “Optimizing HBV Combination Therapy: Dual Targeting of Intracellular Replication and Extracellular Virions with Entecavir and HBVZ10”.   He will be joined by collaborators and SAB Board members: Dr. Fabien Zoulim, MD, PhD, Professor of Medicine at Lyon University and Head of Hepatology Hospices and Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Dr. Jianming Hu, MD, PhD, Professor, Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine,